Sermo adds breakthrough indications search to drug ratings

Sermo announces new feature for its pioneering Drug Ratings platform

Sermo — the largest global social network for physicians – today announced a new feature for its pioneering Drug Ratings platform. In addition to allowing physicians to rate and review prescription drugs according to their own clinical experiences, Sermo Drug Ratings now enables physicians to search for and research prescription drugs by FDA-approved indications.

“Drugs don’t walk into the doctor’s office – patients with conditions do. Doctors tend to think of the patient’s condition first and then think of the available treatment options. Now that physicians can search the Drug Ratings database by indication, they can discover the highest ranked treatment approaches for each indication as well as evaluate how peers rate all approved drugs against each other,” said Sermo CEO Peter Kirk. “Drug ratings for doctors, by doctors are an entirely new resource in medicine, enabling doctors to discover new and physician-preferred treatment options for patients in real time.”

With the new feature physicians can evaluate different classes of drugs against each other for treating specific conditions, or compare unique brands. They can examine the drug’s overall rating, as well as see how other physicians rank classes and drugs on efficacy, safety, tolerability, accessibility, and adherence. This enables doctors to find information as quickly or in as much detail as they need.

Since Drug Ratings launched in May, Sermo physicians have submitted an additional 100,000 ratings, bringing the total to 350,000, and an additional 3,000 comments, raising the number of insights to 23,000. An additional 23,355 physicians from 97 countries have searched the database to read peer reviews in that time. The database now includes over 3,000 drugs rated and ranked, more than 1,000 of which have over 100 ratings.

Hypercholesterolemia rating

If a patient were to walk into a doctor’s office today with hypercholesterolemia, the treating physician could quickly query the Drug Ratings database right from the exam room to see what other doctors think of the available FDA-approved treatment options. They would see that statins are among the highest ranked drug classes for the condition, and that while physicians rate Crestor as the single best approved drug generally, Lipitor is ranked higher on accessibility – a subtlety that may be very important for some patients.

Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. Integrated into the Sermo social network, Drug Ratings gives physicians a clinical decision support tool where they can research, rate, and share their direct experience on specific drugs.

About Sermo & Sermo Drug Ratings

Sermo is the leading global social network for physicians where close to 800,000 fully verified and licensed physicians from more than 150 countries talk real-world medicine, review what peers think of different treatment options – including ratings and comments on prescription drugs – collectively solve cases, respond to healthcare polls, and earn honorarium from surveys.

Drug Ratings was developed by Sermo and Sermo physicians. The statistical methodology behind Ratings was developed and verified independently by biostatistics consultants led by Lee-Jen Wei of the Blue Null Consulting Group.

Sermo is also the world’s largest healthcare professional (HCP) polling company. The Sermo research network is comprised of 1.8 million HCPs and includes 40 percent of the U.S. physician population. Most of the 700,000 surveys Sermo conducts annually are among specialist physicians – over 70 percent of physician members are specialists. Learn more at

Media Contact:
Liz Wells, Racepoint Global; o:+1 202 517 1386